Overview

A Study Of Zy-19489 Administered Via Oral Route To Investigate The Safety, Tolerability And Pharmacokinetics In Healthy Adult Human Subjects

Status:
Recruiting
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
A Randomized, Double Blind, Parallel, Placebo-Control, Study Of ZY-19489 Administered Via Oral Route To Investigate The Safety, Tolerability And Pharmacokinetics In Healthy Adult Human Subjects aged between 18-55 years old (Both Inclusive).
Phase:
Phase 1
Details
Lead Sponsor:
Cadila Healthcare Limited